Clinical Detection and Treatment of Pancreatic Neuroendocrine Tumors

  • Jamie C. Mitchell
Part of the Molecular Pathology Library book series (MPLB, volume 3)


Pancreatic endocrine neoplasms (PEN) typically generate a great deal of clinician interest because of the rarity with which they occur and their associated hormonal syndromes. While their rarity has limited research efforts into the pathophysiology of these tumors to some extent, recent advances in molecular biology techniques have allowed investigators to provide new insights into the pathogenesis of these lesions allowing the development of novel techniques for the diagnosis, localization, and treatment of PENs.


Neuroendocrine Tumor Vasoactive Intestinal Peptide Vascular Endothelial Growth Factor Receptor Carcinoid Tumor Pancreatic Polypeptide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Stridsberg M, Oberg K, Li Q, Engstrom U, Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol. 1995;144(1):49–59.CrossRefPubMedGoogle Scholar
  2. 2.
    Nobels FR, Kwekkeboom DJ, Bouillon R, Lamberts SW. Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur J Clin Invest. 1998;28(6):431–440.CrossRefPubMedGoogle Scholar
  3. 3.
    Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab. 1997;82(8):2622–2628.CrossRefPubMedGoogle Scholar
  4. 4.
    Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999;86(5):858–865.CrossRefPubMedGoogle Scholar
  5. 5.
    Tomassetti P, Migliori M, Simoni P, et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol. 2001;13(1):55–58.CrossRefPubMedGoogle Scholar
  6. 6.
    Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997;8(7):685–690.CrossRefPubMedGoogle Scholar
  7. 7.
    Adrian TE, Bloom SR, Bryant MG, Polak JM, Heitz PH, Barnes AJ. Distribution and release of human pancreatic polypeptide. Gut. 1976;17(12):940–944.CrossRefPubMedGoogle Scholar
  8. 8.
    Bloom SR, Adrian TE, Polak JM. Pancreatic polypeptide from pancreatic endocrine tumours. Lancet. 1980;2(8202):1026.CrossRefPubMedGoogle Scholar
  9. 9.
    Oberg K, Grimelius L, Lundqvist G, Lorelius LE. Update on pancreatic polypeptide as a specific marker for endocrine tumours of the pancreas and gut. Acta Med Scand. 1981;210(3):145–152.PubMedGoogle Scholar
  10. 10.
    Srivastava A, Padilla O, Fischer-Colbrie R, Tischler AS, Dayal Y. Neuroendocrine secretory protein-55 (NESP-55) expression discriminates pancreatic endocrine tumors and pheochromocytomas from gastrointestinal and pulmonary carcinoids. Am J Surg Pathol. 2004;28(10):1371–1378.CrossRefPubMedGoogle Scholar
  11. 11.
    Stridsberg M, Eriksson B, Oberg K, Janson ET. A panel of 11 region-specific radioimmunoassays for measurements of human chromogranin A. Regul Pept. 2004;117(3):219–227.CrossRefPubMedGoogle Scholar
  12. 12.
    Oberg K. Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment. Curr Opin Oncol. 2005;17(4):386–391.CrossRefPubMedGoogle Scholar
  13. 13.
    Li S, Beheshti M. The radionuclide molecular imaging and therapy of neuroendocrine tumors. Curr Cancer Drug Targets. 2005;5(2):139–148.CrossRefPubMedGoogle Scholar
  14. 14.
    Virgolini I, Traub T, Leimer M, et al. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. Q J Nucl Med. 2000;44(1):50–58.PubMedGoogle Scholar
  15. 15.
    Breeman WA, Kwekkeboom DJ, Kooij PP, et al. Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med. 1995;36(4):623–627.PubMedGoogle Scholar
  16. 16.
    Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20(8):716–731.CrossRefPubMedGoogle Scholar
  17. 17.
    Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27(3):273–282.CrossRefPubMedGoogle Scholar
  18. 18.
    Virgolini I, Patri P, Novotny C, et al. Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol. 2001;12(suppl 2):S41-S45.CrossRefPubMedGoogle Scholar
  19. 19.
    Kwekkeboom DJ, Bakker WH, Kooij PP, et al. [177Lu-DOT-AOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med. 2001;28(9):1319–1325.CrossRefPubMedGoogle Scholar
  20. 20.
    Virgolini I, Raderer M, Kurtaran A, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med. 1994;331(17):1116–1121.CrossRefPubMedGoogle Scholar
  21. 21.
    Thakur ML, Marcus CS, Saeed S, et al. 99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans. J Nucl Med. 2000;41(1):107–110.PubMedGoogle Scholar
  22. 22.
    Wank SA. G protein-coupled receptors in gastrointestinal physiology I CCK receptors: an exemplary family. Am J Physiol. 1998;274(4 Pt 1):G607-G613.PubMedGoogle Scholar
  23. 23.
    Behr TM, Jenner N, Radetzky S, et al. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med. 1998;25(4):424–430.CrossRefPubMedGoogle Scholar
  24. 24.
    Reubi JC, Waser B, Schaer JC, et al. Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur J Nucl Med. 1998;25(5):481–490.CrossRefPubMedGoogle Scholar
  25. 25.
    Kwekkeboom DJ, Bakker WH, Kooij PP, et al. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med. 2000;27(9):1312–1317.CrossRefPubMedGoogle Scholar
  26. 26.
    Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman AB. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol. 2004;151(1):15–27.CrossRefPubMedGoogle Scholar
  27. 27.
    Bombardieri E, Seregni E, Villano C, Chiti A, Bajetta E. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med Mol Imaging. 2004;48(2):150–163.PubMedGoogle Scholar
  28. 28.
    Sundin A, Eriksson B, Bergstrom M, Langstrom B, Oberg K, Orlefors H. PET in the diagnosis of neuroendocrine tumors. Ann N Y Acad Sci. 2004;1014:246–257.CrossRefPubMedGoogle Scholar
  29. 29.
    Koopmans KP, Neels OC, Kema IP, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol. 2008;26(9):1489–1495.CrossRefPubMedGoogle Scholar
  30. 30.
    Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med. 2002;32(2):110–122.CrossRefPubMedGoogle Scholar
  31. 31.
    Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002;32(2):123–132.CrossRefPubMedGoogle Scholar
  32. 32.
    Buscombe JR, Caplin ME, Hilson AJ. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med. 2003;44(1):1–6.PubMedGoogle Scholar
  33. 33.
    Wiseman GA, Kvols LK. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Semin Nucl Med. 1995;25(3):272–278.CrossRefPubMedGoogle Scholar
  34. 34.
    Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol. 2007;46(6):723–734.CrossRefPubMedGoogle Scholar
  35. 35.
    de Jong M, Breeman WA, Bakker WH, et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res. 1998;58(3):437–441.PubMedGoogle Scholar
  36. 36.
    Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0), Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30(3):417–422.CrossRefPubMedGoogle Scholar
  37. 37.
    Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46(suppl 1):62S-66S.PubMedGoogle Scholar
  38. 38.
    Oddstig J, Bernhardt P, Nilsson O, Ahlman H, Forssell-Aronsson E. Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro. Nucl Med Biol. 2006;33(7):841–846.CrossRefPubMedGoogle Scholar
  39. 39.
    Capello A, Krenning E, Bernard B, Reubi JC, Breeman W, de Jong M. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2005;32(11):1288–1295.CrossRefPubMedGoogle Scholar
  40. 40.
    Rogers BE, Zinn KR, Lin CY, Chaudhuri TR, Buchsbaum DJ. Targeted radiotherapy with [(90)Y]-SMT 487 in mice bearing human nonsmall cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector. Cancer. 2002;94(4 suppl):1298–1305.CrossRefPubMedGoogle Scholar
  41. 41.
    Freeman SM, Abboud CN, Whartenby KA, et al. The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53(21):5274–5283.PubMedGoogle Scholar
  42. 42.
    ter Horst M, Verwijnen SM, Brouwer E, et al. Locoregional delivery of adenoviral vectors. J Nucl Med. 2006;47(9):1483–1489.PubMedGoogle Scholar
  43. 43.
    de Visser M, Verwijnen SM, de Jong M. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy. Cancer Biother Radiopharm. 2008;23(2):137–157.CrossRefPubMedGoogle Scholar
  44. 44.
    Hofland LJ, Capello A, Krenning EP, de Jong M, van Hagen MP. Induction of apoptosis with hybrids of Arg-Gly-Asp molecules and peptides and antimitotic effects of hybrids of cytostatic drugs and peptides. J Nucl Med. 2005;46(suppl 1):191S-198S.PubMedGoogle Scholar
  45. 45.
    Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008;26(8):1316–1323.CrossRefPubMedGoogle Scholar
  46. 46.
    Yao JC. Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab. 2007;21(1):163–172.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Jamie C. Mitchell
    • 1
  1. 1.Department of Endocrine SurgeryThe Cleveland ClinicClevelandUSA

Personalised recommendations